We are live on ! Find out more
AICPI

ABG Innovation Capital Partners III Portfolio holdings

AUM $64.5K
1-Year Est. Return 1.01%
This Fund
S&P 500
This Quarter Est. Return
-10.77%
1 Year Est. Return
+1.01%
3 Year Est. Return
+5.56%
5 Year Est. Return
-85.52%
10 Year Est. Return
–
AUM
$1.31M
AUM Growth
-$165K
Cap. Flow
-$4.02K
Cap. Flow %
-0.31%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
GNCA
Genocea Biosciences, Inc.
GNCA
+$4K
2
ACGN
Aceragen Inc
ACGN
+$18

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSTL icon
1
Castle Biosciences
CSTL
$1.02B
$792K 60.43%
33,626
– –
WHWK
2
Whitehawk Therapeutics
WHWK
$263M
$342K 26.12%
26,666
– –
SYBX
3
DELISTED
Synlogic
SYBX
$156K 11.95%
13,727
– –
ACGN
4
DELISTED
Aceragen Inc
ACGN
$19.7K 1.5%
3,309
-3
-0.1% -$18
GNCA
5
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-375,000
Closed -$4K

Similar funds

FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
SNN
Shen Neil Nanpeng $36.3K AUM 179.45% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
NA
Newport Asia San Francisco, California $2.21M AUM
IVSFI
IA Venture Strategies Fund II New York $4.08M AUM 174.71% 1-Year Est. Return
FFGM
Founders Fund Growth Management San Francisco, California $7.04M AUM 82.06% 1-Year Est. Return

ABG Innovation Capital Partners III's Q4 2022 Portfolio in Review

As of Q4 2022, ABG Innovation Capital Partners III held 5 positions worth $1.31M, down 11% from $1.48M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ABG Innovation Capital Partners III's Q4 2022 filing shows 1 reduced and 1 closed positions. The largest sale was Genocea Biosciences, Inc., an estimated $4K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ABG Innovation Capital Partners III's biggest Q4 2022 reduction was Aceragen Inc, cutting an estimated $18.
  • ABG Innovation Capital Partners III fully exited Genocea Biosciences, Inc. in Q4 2022, selling an estimated $4K.
  • ABG Innovation Capital Partners III's ten largest holdings make up 100% of its $1.31M portfolio in Q4 2022.
  • ABG Innovation Capital Partners III opened 0 new positions and closed 1 in Q4 2022.
  • ABG Innovation Capital Partners III's portfolio value fell 11% quarter-over-quarter to $1.31M.

Based on ABG Innovation Capital Partners III's 13F filing for Q4 2022, filed 14 Feb 2023.